Mahmood Ahmad
Tahir Heart Institute
author@example.com

CT.gov Sponsor Overdue Debt

Which named CT.gov sponsors accumulate the deepest unresolved overdue years once silence is measured beyond the two-year results deadline rather than by counts alone? We analysed 249,507 eligible older closed interventional studies from the March 29, 2026 full-registry snapshot. We summed unresolved years beyond the two-year mark for each named sponsor with at least 100 older studies and compared that debt with missing-results stock and mean unresolved age. GlaxoSmithKline carried the largest sponsor overdue-debt stock at 17,950 unresolved years, followed by Boehringer Ingelheim at 15,166 and National Cancer Institute at 14,020. Boehringer Ingelheim also carried the heaviest large-sponsor mean unresolved age at 17.7 years, while Sanofi and AstraZeneca remained debt holders on stock. Chronic CT.gov silence is not only how many studies remain overdue, but how long large sponsor portfolios stay unresolved after deadline. Overdue debt is a registry-timing measure based on time beyond the two-year mark and does not assign legal responsibility or explain delay.

Outside Notes

Type: methods
Primary estimand: Total unresolved years beyond the two-year results mark among named lead sponsors with at least 100 older studies
App: CT.gov Sponsor Overdue Debt dashboard
Data: 249,507 eligible older closed interventional studies with sponsor-level overdue debt and mean unresolved age fields
Code: https://github.com/mahmood726-cyber/ctgov-sponsor-overdue-debt
Version: 1.0.0
Validation: FULL REGISTRY RUN

References

1. ClinicalTrials.gov API v2. National Library of Medicine. Accessed March 29, 2026.
2. DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet. 2020;395(10221):361-369.
3. Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov. N Engl J Med. 2016;375(20):1998-2004.

AI Disclosure

This work represents a compiler-generated evidence micro-publication built from structured registry data and deterministic summary code. AI was used as a constrained coding and drafting assistant for interface generation, packaging, and prose refinement, not as an autonomous author. The analytical choices, interpretation, and final outputs were reviewed by the author, who takes responsibility for the content.